Osteoarthritis Definition: What Happens Inside the Joint

Osteoarthritis is a chronic joint disease in which the cartilage, bone, and surrounding tissues of a joint gradually break down, causing pain, stiffness, and loss of function. Roughly 595 million people worldwide had the condition as of 2020, making it the single most common form of arthritis. While many people still think of it as simple “wear and tear” on cartilage, researchers now recognize osteoarthritis as a disease of the entire joint, involving bone, ligaments, the joint lining, and even the muscles and nerves around it.

More Than Worn-Out Cartilage

For most of the twentieth century, osteoarthritis was described almost entirely in terms of cartilage loss. Cartilage is the smooth, rubbery tissue that caps the ends of bones inside a joint, and when it thins or cracks, bones can grind against each other painfully. That much is true. But stopping the definition there misses most of what is actually going on. Research over the past two decades has reframed osteoarthritis as a whole-joint disease, meaning every tissue in and around the joint is involved: the cartilage itself, the bone just beneath it (called subchondral bone), the synovial membrane lining the joint capsule, the menisci in the knee, the ligaments holding the joint together, and the muscles that stabilize it.

This redefinition matters because it changes how doctors think about treatment and prevention. If cartilage were the whole story, you would only need to protect or replace that one tissue. Because every structure in the joint participates, interventions that target muscle strength, bone remodeling, or inflammation in the joint lining all have a potential role.

What Happens Inside an Osteoarthritic Joint

Several processes run in parallel once osteoarthritis takes hold, and they tend to feed on each other.

The cartilage cells, called chondrocytes, start behaving abnormally. In a healthy adult joint, chondrocytes quietly maintain the surrounding matrix of collagen and proteoglycans that gives cartilage its strength and springiness. In osteoarthritis, those cells shift toward a state resembling what happens in growing bones during childhood: they enlarge, start producing enzymes that chew up the cartilage matrix, and lose their ability to repair damage. This shift is sometimes called chondrocyte hypertrophy, and it is considered one of the key drivers of permanent cartilage loss.

Beneath the cartilage, the subchondral bone begins remodeling in response to abnormal mechanical stresses. Tiny fractures accumulate in the bone just below the joint surface, and the bone responds by thickening and stiffening, a process visible on X-rays as subchondral sclerosis. Bony outgrowths called osteophytes, often described as “bone spurs,” form at the joint margins. On MRI, early bone changes show up as bone marrow lesions, areas of swelling within the bone itself.

The synovial membrane, the thin tissue lining the inside of the joint capsule, also becomes inflamed. Although osteoarthritis is not an autoimmune disease like rheumatoid arthritis, low-grade inflammation plays a real role. A network of signaling molecules called cytokines tips the balance inside the joint toward breakdown rather than repair, accelerating the loss of cartilage and bone structure.

⁴

All three processes, the cartilage cell changes, the bone remodeling, and the synovial inflammation, reinforce each other in a destructive loop. That is why osteoarthritis tends to progress over time, though the rate of progression varies enormously from person to person.

How Common It Is

Osteoarthritis is staggeringly common. A systematic analysis published in The Lancet Rheumatology estimated that about 595 million people had the condition globally in 2020, equal to roughly 7.6 percent of the world’s population. Total cases had more than doubled since 1990. The knee is the most frequently affected site, and the burden is projected to rise sharply: knee osteoarthritis cases alone are expected to climb by about 75 percent between 2020 and 2050, while hip osteoarthritis may increase by nearly 79 percent over the same period.

⁵

The disease is more common in women than in men, and prevalence climbs with age, peaking in the oldest age groups. But age alone does not explain the trend. The global age-standardized incidence rate, which accounts for the fact that populations are aging, also rose between 1990 and 2021, suggesting that factors beyond demographics are at work.

⁶

For adults over 70, osteoarthritis is the seventh leading cause of years lived with disability worldwide. That ranking captures something important: osteoarthritis rarely kills anyone, but it erodes quality of life over decades.

⁷

How Doctors Diagnose It

There is no single blood test for osteoarthritis. Diagnosis is almost always clinical, meaning it rests on a combination of your symptoms, a physical exam, and sometimes imaging. The American College of Rheumatology developed classification criteria for osteoarthritis at different joint sites, and these remain widely used.

For the hip, the criteria center on hip pain combined with findings like limited internal rotation, morning stiffness lasting under an hour, and age over 50. When X-rays are added, doctors look for osteophytes and narrowing of the joint space between the bones. The combined clinical-plus-radiographic criteria achieve a sensitivity of about 89 percent and a specificity of about 91 percent, meaning they correctly identify most people who have the disease while ruling out most who do not.

⁸

For the hand, clinicians look for hard, bony enlargements at specific finger joints, particularly the joints closest to the fingertips. If at least two of ten selected joints show this bony enlargement, and the knuckle joints are not conspicuously swollen, hand osteoarthritis is the likely diagnosis.

⁹

When X-rays are used, the most familiar system is the Kellgren-Lawrence scale, which grades severity from 0 (no disease) to 4 (severe). The scale weighs the presence of osteophytes heavily, and some researchers have noted that it can overemphasize bone spurs relative to the actual narrowing of the cartilage space, which arguably matters more for function.

¹⁰

Why Pain and X-Ray Findings Often Disagree

One of the most confusing aspects of osteoarthritis is the weak relationship between what an X-ray shows and how much pain a person actually feels. Some people with severely narrowed joint spaces on imaging report surprisingly little discomfort. Others have mild-looking X-rays but are in significant pain. This mismatch is not in anyone’s head. It reflects real differences in how the nervous system processes pain signals.

Research using quantitative sensory testing found that people with high levels of knee pain but only mild radiographic changes showed heightened pain sensitivity at body sites far from the knee itself. That pattern suggests the central nervous system has turned up its pain volume, a process called central sensitization. Conversely, people with severe X-ray changes but low pain levels appeared to be resistant to that amplification.

¹¹

This has practical consequences. If your X-ray looks mild but your pain is real and persistent, that does not mean nothing is wrong or that you are exaggerating. And if your X-ray looks alarming but you feel fine, aggressive treatment may not be warranted. The disconnect also complicates research, because trials often define “severe osteoarthritis” by imaging alone, potentially grouping together people whose pain experience and treatment needs are very different.

Risk Factors Beyond Getting Older

Age is the biggest single risk factor for osteoarthritis, but it is far from the only one, and framing the disease as inevitable aging sells short what is actually a complex interplay of mechanical, metabolic, and genetic forces.

High body mass index is among the most important modifiable risk factors. The Lancet analysis attributed about a fifth of the global osteoarthritis burden to high BMI.

¹²

That number alone is striking, but the mechanism is not purely about extra load on weight-bearing joints. Obese individuals also have roughly double the rate of hand osteoarthritis compared to lean individuals, even though hands bear almost no body weight. Excess fat tissue appears to harm joints systemically through inflammatory and metabolic pathways, not just mechanically.

¹³

Joint injuries are another major pathway. People who tear an anterior cruciate ligament (ACL) in the knee face a substantially elevated risk of developing what is called post-traumatic osteoarthritis, sometimes within a decade or two of the initial injury. The mechanism involves structural instability, altered biomechanics, and a burst of inflammation at the time of injury that may set destructive processes in motion long before symptoms appear.

¹⁴

Developmental conditions can set the stage even earlier. Hip dysplasia, where the hip socket does not fully cover the ball of the femur, is a known risk factor for hip osteoarthritis. In people with symptomatic dysplasia who do not receive surgical intervention, the altered joint mechanics can lead to cartilage breakdown at a relatively young age.

¹⁵

Different Joints, Surprisingly Different Diseases

Osteoarthritis of the knee, hip, and hand are often discussed as if they were the same condition in different locations. Genetically and pathologically, that picture is oversimplified. A twin study examining the genetic underpinning of osteoarthritis at multiple sites found that the so-called “common OA phenotype,” a shared genetic predisposition to osteoarthritis in general, accounted for very little of the variation in hip and knee disease. Genetic factors influencing hand osteoarthritis overlapped somewhat between finger joint groups, but the hip and knee appeared to be largely independent from each other genetically.

¹⁶

The clinical differences extend beyond genetics. Hip and knee osteoarthritis differ in their prevalence patterns, the way they progress, their biomechanical drivers, and even their response to non-surgical treatments.

¹⁷

Symmetry is another clue that something more than simple mechanics is involved. In hands, osteoarthritis tends to appear symmetrically on both sides. In hips and knees, it can be quite lopsided. The degree of symmetry at each joint site hints at how much of the disease at that location is driven by systemic factors versus local biomechanical ones.

¹⁸

How Osteoarthritis Differs From Rheumatoid Arthritis

People frequently confuse osteoarthritis with rheumatoid arthritis, but they are fundamentally different diseases. Rheumatoid arthritis is a systemic autoimmune condition in which the immune system attacks the joint lining, causing widespread inflammation that can affect organs beyond the joints. Blood tests typically show elevated inflammatory markers and the presence of rheumatoid factor, an antibody. Osteoarthritis is a more local disease: it centers on the joint itself, does not cause the same systemic immune disturbance, and does not produce rheumatoid factor or markedly elevated blood inflammation markers.

¹⁹

That said, the line is not as clean as older textbooks suggested. Osteoarthritis does involve inflammation, just at a lower grade than rheumatoid arthritis. Some patients have periods of synovial flare that temporarily mimic the warmth and swelling of an inflammatory arthritis. The distinction is one of degree and mechanism: immune-driven systemic attack in rheumatoid arthritis versus locally driven, low-grade inflammation woven into a biomechanical and metabolic process in osteoarthritis.

The Push Toward Subtyping

One reason osteoarthritis has resisted effective drug treatment is that it is probably not a single disease. Researchers have been working for years to carve it into meaningful subtypes, sometimes called phenotypes or endotypes, in hopes of matching specific treatments to specific patients.

²⁰

A systematic review of knee osteoarthritis phenotyping found that several characteristics tend to cluster together in distinct groups: pain sensitization, psychological distress, radiographic severity, BMI, muscle strength, the degree of inflammation, and the presence of other chronic conditions. Some patients have an inflammatory-dominant pattern; others have a metabolic-dominant pattern driven by obesity and related conditions; still others have a primarily mechanical or post-traumatic profile.

²¹

None of these proposed phenotypes has been validated well enough to guide treatment decisions in everyday clinical practice yet. But the concept matters because it helps explain why a drug that helps one person’s osteoarthritis does nothing for another. It also frames a large part of the research agenda: finding the right treatment for the right subtype is a more realistic goal than finding one treatment that works for everyone.

The Search for Disease-Modifying Drugs

Currently, no approved drug can halt or reverse the structural damage of osteoarthritis. Most treatments manage symptoms: painkillers, anti-inflammatory drugs, physical therapy, and eventually joint replacement surgery when the joint is badly degraded. The term “disease-modifying osteoarthritis drug,” or DMOAD, refers to a drug that would slow or stop the structural progression of the disease, measured by outcomes such as preservation of joint space width or cartilage volume, not just pain relief.

²²

Designing trials for DMOADs is fiendishly difficult. Osteoarthritis progresses slowly in most people, so trials must run for years. The pain-imaging disconnect described earlier means that structural improvement on imaging does not guarantee the patient feels better. And the heterogeneity of the disease means a drug that modifies one biological pathway may only help the fraction of patients whose disease is driven by that pathway. One analysis of clinical trial design estimated that hundreds to thousands of patients per group would be needed to demonstrate a 50 percent structural benefit, depending on how strictly “meaningful progression” was defined.

²³

Osteoarthritis in an Evolutionary Light

Osteoarthritis is not unique to modern humans. It shows up in the fossil record and in other living species. But its pattern across species offers clues about why humans are so vulnerable to it.

A comparative study of great apes found that all ape species showed significantly less spinal osteoarthritis than humans, and generally less disease in the major limb joints as well. The difference likely reflects the biomechanical consequences of walking upright: bipedal locomotion concentrates forces through the spine, hips, and knees in ways that quadrupedal movement does not.

²⁴

Recent genetic work has made this connection more precise. An analysis of skeletal proportions and their genetic basis found specific associations between the shape of the hip and knee and the risk of osteoarthritis at those joints. In other words, the genes that made our skeletons suited for upright walking may also have made those joints more susceptible to degenerative disease.

²⁵

Osteoarthritis has even been documented in marine mammals and a range of land species. A study of skeletal remains from 24 mammal species, including dolphins and dugongs, found osteoarthritis lesions across all of them, though at low rates in the marine animals. In dolphins, the elbow-equivalent joint was most commonly affected; in dugongs, the lumbar spine took the brunt. The disease, it seems, is a very old biological problem that shows up wherever joints bear repeated loads, regardless of whether those joints belong to a biped, a quadruped, or a swimmer.

²⁶